ProMIS initiates Phase 1b PRECISE-AD trial of PMN310 in Alzheimer's disease

ProMIS Neurosciences Inc.

Phase 1b PRECISE-AD trial initiated; evaluating PMN310 in 100 patients with early Alzheimer's over 12 months.
PMN310 selectively targets toxic amyloid-beta oligomers, avoiding plaque to reduce ARIA risk associated with existing therapies.
Phase 1a data showed favorable safety/tolerability profile and drug concentrations in CSF supporting target engagement.
Certain interim data from PRECISE-AD expected in first half of 2026.
Trial will assess safety, tolerability, PK, biomarkers, and clinical efficacy measures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.